Cryoballoon Ablation Is Non‑Inferior to Radiofrequency for 1‑Year Arrhythmia Control in Persistent AF — but Left Atrium Shrinks Less: Insights from the CRRF‑PeAF Trial

Cryoballoon Ablation Is Non‑Inferior to Radiofrequency for 1‑Year Arrhythmia Control in Persistent AF — but Left Atrium Shrinks Less: Insights from the CRRF‑PeAF Trial

The randomized CRRF‑PeAF trial (n=499) found cryoballoon pulmonary vein isolation non‑inferior to radiofrequency ablation for 1‑year atrial tachyarrhythmia recurrence in persistent atrial fibrillation, but radiofrequency produced greater left atrial reverse remodelling.
Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while numerically more major bleeding occurred with rivaroxaban.